Tags

Type your tag names separated by a space and hit enter

The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata.
J Am Acad Dermatol. 2001 Jan; 44(1):73-6.JA

Abstract

BACKGROUND

Highly variable results of topical diphenylcyclopropenone (DPCP) in the treatment of alopecia areata have been reported so far.

OBJECTIVE

The purposes of our study were to evaluate the efficacy and tolerability of DPCP in the treatment of chronic, extensive alopecia areata and to assess the long-term overall benefit of treatment.

METHODS

Fifty-six patients with chronic, extensive alopecia areata were enrolled in an open-label clinical trial. After sensitization with 2% DPCP, progressively higher concentrations beginning at 0.001% were applied weekly for 6 to 12 months to one side of the scalp.

RESULTS

Fifty-two of 56 patients completed therapy. Total regrowth of terminal hair was achieved in 25 of 52 patients (48%) at 6 months. The most frequent side effect was an eczematous reaction at the site of application. Notably, persistent response was observed in 60% of these patients after 6 to 18 months of follow-up (mean, 12 months).

CONCLUSION

Topical DPCP treatment for alopecia areata is effective and well tolerated and provides prolonged therapeutic benefits.

Authors+Show Affiliations

Department of Dermatology, University of L'Aquila, Italy. chimenti@univaq.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

11148480

Citation

Cotellessa, C, et al. "The Use of Topical Diphenylcyclopropenone for the Treatment of Extensive Alopecia Areata." Journal of the American Academy of Dermatology, vol. 44, no. 1, 2001, pp. 73-6.
Cotellessa C, Peris K, Caracciolo E, et al. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol. 2001;44(1):73-6.
Cotellessa, C., Peris, K., Caracciolo, E., Mordenti, C., & Chimenti, S. (2001). The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. Journal of the American Academy of Dermatology, 44(1), 73-6.
Cotellessa C, et al. The Use of Topical Diphenylcyclopropenone for the Treatment of Extensive Alopecia Areata. J Am Acad Dermatol. 2001;44(1):73-6. PubMed PMID: 11148480.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. AU - Cotellessa,C, AU - Peris,K, AU - Caracciolo,E, AU - Mordenti,C, AU - Chimenti,S, PY - 2001/1/10/pubmed PY - 2001/3/3/medline PY - 2001/1/10/entrez SP - 73 EP - 6 JF - Journal of the American Academy of Dermatology JO - J. Am. Acad. Dermatol. VL - 44 IS - 1 N2 - BACKGROUND: Highly variable results of topical diphenylcyclopropenone (DPCP) in the treatment of alopecia areata have been reported so far. OBJECTIVE: The purposes of our study were to evaluate the efficacy and tolerability of DPCP in the treatment of chronic, extensive alopecia areata and to assess the long-term overall benefit of treatment. METHODS: Fifty-six patients with chronic, extensive alopecia areata were enrolled in an open-label clinical trial. After sensitization with 2% DPCP, progressively higher concentrations beginning at 0.001% were applied weekly for 6 to 12 months to one side of the scalp. RESULTS: Fifty-two of 56 patients completed therapy. Total regrowth of terminal hair was achieved in 25 of 52 patients (48%) at 6 months. The most frequent side effect was an eczematous reaction at the site of application. Notably, persistent response was observed in 60% of these patients after 6 to 18 months of follow-up (mean, 12 months). CONCLUSION: Topical DPCP treatment for alopecia areata is effective and well tolerated and provides prolonged therapeutic benefits. SN - 0190-9622 UR - https://www.unboundmedicine.com/medline/citation/11148480/The_use_of_topical_diphenylcyclopropenone_for_the_treatment_of_extensive_alopecia_areata_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(01)90560-2 DB - PRIME DP - Unbound Medicine ER -